The development of D3R-selective antagonists (including GSK 598809 and ABT-925) as well as the D3R-preferring D3R/D2R antagonist S33138 (intended for treating schizophrenia and drug abuse) were all discontinued due to insufficient activities(Figure 1) [7]. The gene discussed is DRD2; the disease is schizophrenia.